14.10.2019 • News

BASF Construction Chemicals Exit Stalls

© LafargeHolcim Ltd. Photographer: Rüdiger Nehmzow
© LafargeHolcim Ltd. Photographer: Rüdiger Nehmzow

BASF’s planned exit from the construction chemicals sector may take longer than expected, reports from the market suggest.

In the latest setback, sources speaking to the Bloomberg news agency said Swiss cement manufacturer LafargeHolcim, the sole remaining company interested in the additives portfolio, has opted not to bid because it considers the price too high.

The cement producer also reportedly had concerns about how long it would take for BASF to execute the sale, which could hurt the performance and integration of the business. The division produces mortars and cement additives, as well as waterproofing materials and sealants.

LafargeHolcim is said to have been competing with private equity investor Cinven for the business; however, both it and roofing materials specialist Standard Industries have since stepped back from the plate. Cinven owns construction chemicals producer Chryso, which offer synergies but also pose antitrust issues, the news agency noted.

BASF kicked off the sales process In January this year, saying it expected to divest all the activities acquired in 2006 from the former Degussa (now Evonik) for a total of about €2.7 billion, potentially by the end of 2019.

Announcing a strategic review of the business in October last year, then new-CEO Martin Brudermüller suggested that a partnership might be considered if targets for the divestment were not met.

Bloomberg’s analysts now expect the focus of the sale to shift from the industrial to the private equity sector. However, the news agency added that several other private equity buyers have already walked away from the bidding, with some saying BASF did not provide detailed information on earnings.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.